Findings from HERTHENA-Lung02 showed that the key secondary endpoint of overall survival did not meet statistical significance.

Susan Galbraith of AstraZeneca and Ken Takeshita of Daiichi Sankyo echoed the sentiment, highlighting the potential for ENHERTU to transform the treatment landscape and delay disease progression.

TROPION-Lung02 and TROPION-Lung04 phase 1b results support combination of Daiichi Sankyo and AstraZeneca’s DATROWAY ... of certain patients with non-small cell lung cancer," said Ken Takeshita, MD, ...

Daiichi Sankyo and MSD have voluntarily withdrawn the biologics licence application (BLA) in the US for their HER3-directed ...

Daiichi Sankyo research and development global head Ken Takeshita said: “While we are disappointed with the OS results of HERTHENA-Lung02, we are conducting further biomarker analyses to better ...

(RTTNews) - The Biologics License Application (BLA) seeking accelerated approval of patritumab deruxtecan, co-developed by Merck & Co Inc. (MRK) and Daiichi ... said Ken Takeshita, Global Head ...

“EGFR-mutated non-small cell lung cancer has proven to be difficult-to-treat in the second-line metastatic setting and beyond,” said Ken Takeshita, MD, Global Head, R&D, Daiichi ...

A therapy at the center of their $22 billion alliance failed to extend survival in a type of lung tumor, leading the ...

When Merck & Co. and Daiichi Sankyo last year received an FDA complete ... multiple clinical trials across 15 types of cancer," Ken Takeshita, M.D., Daiichi's global head of R&D, said in a statement.

"EGFR-mutated non-small cell lung cancer has proven to be difficult-to-treat in the second-line metastatic setting and beyond," said Ken Takeshita, MD, Global Head, R&D, Daiichi Sankyo. "While we are ...

“EGFR-mutated non-small cell lung cancer has proven to be difficult to treat in the second-line metastatic setting and beyond,” said Ken Takeshita, MD, Global Head, R&D, Daiichi Sankyo.